AstraZeneca (NASDAQ:AZN) had its target price hoisted by SVB Leerink from $69.00 to $71.00 in a report issued on Monday morning, Benzinga reports. SVB Leerink currently has an outperform rating on the stock.
AZN has been the subject of several other reports. Morgan Stanley reiterated an overweight rating on shares of AstraZeneca in a research report on Friday. JPMorgan Chase & Co. assumed coverage on AstraZeneca in a research report on Thursday, August 12th. They set an overweight rating for the company. UBS Group restated a buy rating on shares of AstraZeneca in a research report on Thursday, June 17th. Finally, Citigroup restated a buy rating on shares of AstraZeneca in a research report on Wednesday, July 21st. One analyst has rated the stock with a sell rating, two have assigned a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat.com, AstraZeneca presently has a consensus rating of Buy and a consensus price target of $123.00.
Shares of AstraZeneca stock opened at $58.50 on Monday. The firm has a market capitalization of $181.25 billion, a price-to-earnings ratio of 40.63, a PEG ratio of 1.21 and a beta of 0.53. AstraZeneca has a fifty-two week low of $46.48 and a fifty-two week high of $60.93. The company has a debt-to-equity ratio of 1.54, a quick ratio of 1.01 and a current ratio of 1.23. The stock has a 50 day moving average of $57.80 and a 200 day moving average of $55.45.
The firm also recently declared a semi-annual dividend, which was paid on Monday, September 13th. Shareholders of record on Friday, August 13th were paid a $0.45 dividend. This represents a yield of 2.4%. The ex-dividend date of this dividend was Thursday, August 12th. AstraZeneca’s dividend payout ratio is presently 68.16%.
Institutional investors have recently bought and sold shares of the business. Activest Wealth Management acquired a new position in shares of AstraZeneca in the second quarter valued at approximately $26,000. Corsicana & Co. acquired a new stake in shares of AstraZeneca during the second quarter worth $30,000. Front Row Advisors LLC lifted its holdings in shares of AstraZeneca by 80.0% during the second quarter. Front Row Advisors LLC now owns 513 shares of the company’s stock worth $30,000 after purchasing an additional 228 shares during the period. Clearstead Advisors LLC lifted its holdings in shares of AstraZeneca by 960.0% during the second quarter. Clearstead Advisors LLC now owns 530 shares of the company’s stock worth $32,000 after purchasing an additional 480 shares during the period. Finally, Ten Capital Wealth Advisors LLC lifted its holdings in shares of AstraZeneca by 112.8% during the second quarter. Ten Capital Wealth Advisors LLC now owns 566 shares of the company’s stock worth $34,000 after purchasing an additional 300 shares during the period. 13.88% of the stock is owned by institutional investors.
AstraZeneca Company Profile
AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Featured Story: History of the Euro STOXX 50 Index
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.